Results 41 to 50 of about 901 (171)

The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice

Scientific Reports, 2021
Schistosoma mansoni is less susceptible to the antiparasitic drug ivermectin than other helminths. By inhibiting the P-glycoprotein or cytochrome P450 3A in mice host or parasites in a murine model, we aimed at increasing the sensitivity of S. mansoni to
Belén Vicente, Julio López-Abán, Juliane Chaccour, Juan Hernández-Goenaga, Patricia Nicolas, Pedro Fernández-Soto, Antonio Muro, Carlos Chaccour   +7 more
doaj   +1 more source

Lack of antiviral activity of darunavir against SARS-CoV-2

International Journal of Infectious Diseases, 2020
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are ...
Sandra De Meyer, Denisa Bojkova, Jindrich Cinatl, Ellen Van Damme, Christophe Buyck, Marnix Van Loock, Brian Woodfall, Sandra Ciesek   +7 more
doaj   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Factors associated with the number of drugs in darunavir/cobicistat regimens. [PDF]

, 2019
Background: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. Objectives: To assess factors associated with the number of drugs in darunavir/cobicistat regimens.
Knobel, Hernando, Torralba, Miguel, Negredo, Eugenia, Boix, Vicente, Martinez, Esteban, González-Doménech, Carmen María, Ocampo, Antonio, Payeras, Antoni, Alejos, Belén, Martin-Carbonero, Luz, Pérez-Elías, María Jesús, Lozano, Fernando, Montero, Marta, Gutierrez, Mar, Sanz, José, González-Cordón, Ana, Garcia-Fraile, Lucio   +16 more
core   +1 more source

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia

Blood Neoplasia
: Azacitidine/venetoclax is the standard treatment for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. Cytochrome P450 3A4 (CYP3A4) is the major metabolizing enzyme for venetoclax, and its inhibition can boost venetoclax.
Niels Westra, Elena Ropero Cerro, Edwin Schilder, Marjolijn N. Lub-de Hooge, Daan J. Touw, Jos G. W. Kosterink, Dana A. Chitu, Emanuele Ammatuna, Saskia K. Klein, Peter E. Westerweel, Marloes Cuijpers, Marjan Cruijsen, Maarten M. F. Corsten, Canan Alhan, Lidwine Tick, Jan Jacob Schuringa, Gerwin Huls, Carolien M. Woolthuis, Thijs H. Oude Munnink   +18 more
doaj   +1 more source

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Pharmaceutics, 2023
Background: The clinical outcomes of antiretroviral drugs may be modified through drug interactions; thus, it is important to update the drug interactions in people living with HIV (PLHIV). Aim: To update clinically relevant drug interactions in PLHIV on
Pedro Amariles, Mónica Rivera-Cadavid, Mauricio Ceballos   +2 more
doaj   +1 more source

Aspectos farmacológicos de darunavir/cobicistat

Enfermedades Infecciosas y Microbiología Clínica, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad bien conocido.
González-Doménech, Carmen María, Palacios-Muñoz, María Rosario, Santos-González, Jesús Leandro   +2 more
openaire   +3 more sources

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

BMC Nephrology, 2020
Background Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).
José Ramón Santos, Ana Merino, Walter E. Haefeli, Cristina Miranda, Marisol Prats, Ioana Bancu, Lucía Bailón, José Moltó   +7 more
doaj   +1 more source

A multidisciplinary, AI‐supported quality improvement intervention to manage polypharmacy in aging people with HIV

HIV Medicine, EarlyView.
Abstract Objectives Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older ...
Jovana Milic, Antonia Pugliese, Michela Belli, Gian Luca Lonardi, Caterina Ruffilli, Tommaso Albano, Marco Visicaro, Martina Ricciardetto, Pierluigi De Cosmo, Chiara Mussi, Francesca Gandolfi, Cristina Mussini, Costantino Grana, Giovanni Guaraldi   +13 more
wiley   +1 more source